# Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Study · id `cardio:ct-nct03011450` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03011450](<https://clinicaltrials.gov/study/NCT03011450>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03011450

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 471 participants.

## Technical summary

Registry record NCT03011450. Randomized; triple masking; primary purpose treatment. Start 2016-11-26 (actual); primary completion 2019-07-05 (actual). Results posted on 2022-10-28.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 471 participants (enrolled count; ClinicalTrials.gov record NCT03011450, source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)
- Started: 2016-11-26 (actual) (ClinicalTrials.gov record NCT03011450, source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)
- Primary completion: 2019-07-05 (actual) (ClinicalTrials.gov record NCT03011450, source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)
- Completion: 2019-07-05 (actual) (ClinicalTrials.gov record NCT03011450, source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)
- Results first posted: 2022-10-28 (ClinicalTrials.gov record NCT03011450, source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)
- Countries: United States; Belarus; Bulgaria; Czechia; Georgia; Hungary; Poland; Russia; Ukraine (ClinicalTrials.gov record NCT03011450, source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03011450-2022-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): K-877
- Intervention (Drug): Fenofibrate
- Intervention (Drug): Placebo (for K-877)
- Lead sponsor: Kowa Research Institute, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Kowa Research Institute, Inc. (`cardio:org-kowa-research-institute-inc`)

## Provenance

Content hash: 1698b330b90f81bdd3418560e3330827790a98da749e0e66cfa5ecd97fcaff76
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
